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Lung cancer specifically non-small cell lung cancer (NSCLC) is one of the 
most devastating cancers. Despite having diverse treatment methods such as surgery, 
chemotherapy, radiation and targeted therapies, the overall 5-year survival rate for 
NSCLC is accounted for only 18.2 %. The high mortality rates for NSCLC are partially 
due to the lack of effective prognostic factors such as biomarkers. Nowadays, plant- 
derived bioactive substances have been making way as potential anticancer agents. 
One such plant is Annona muricata Linn, which is also known as soursop or graviola. 
This plant has been widely reported to contain valuable phytochemical substances that 
could be developed as chemopreventive agents. The antiproliferative and anticancer 
activities of this tropical plant have been demonstrated in in vitro cell culture studies 
as well as in in vivo studies of animals. It has been discovered that A. muricata L. 
extract exerts inhibition against various number of cancer cells, involving multiple 
mechanism of actions. Nonetheless, the mode of action and the molecular interactions 
of the plant have not yet been unveiled for most of these mechanisms. In the current 
study, response surface methodology was utilized to optimize the ultrasonic-assisted 
extraction (UAE) and maceration extraction (ME) of A. muricata L. leaves. Central 
composite design was applied to optimize the antioxidant activity of both extracts. It 
has been found that ME extract showed high antioxidant activity as compared to UAE 
extract with 83.3 % and 31.6 % respectively. However, through cytotoxicity study that 
was done by using MTT assay, UAE extract exhibited significant cytotoxicity effects 
in NSCLC cell line (HLFa) with IC50 of 139.6 p,g/mL as compared to ME extract with 
IC30 of 108.4 p,g/mL. The effect of the extracts on nitric oxide (NO) production in 
HLFa cells was also evaluated using Griess reagent system assay. Both extracts 
reduced the release of nitrite in the cell supernatant which indicated the reduction in 
NO production. Caspase 3/7 apoptosis assay was used to detect the presence of 
apoptotic machinery in HLFa cells after incubation. The mRNA expression of several 
genes namely HMGB1, BCL2 and BAX  were quantified. The mechanistic evalution of 
the results showed the possibility o f involvement of these genes in A. muricata L. 
anticancer effects. At the end of this study, in silico molecular docking interaction of 
several phytoconstituents of A. muricata L. was analysed against Bcl-2 antiapoptotic 
proteins namely Bcl-2, Bcl-w and Mcl-1. The stability o f complexes formed was 
evaluated using molecular dynamic simulation. Anonaine was also detected in UAE 
and ME extracts through HPLC screening process with 10.6 ppm and 10.7 ppm, 
respectively.
Kanser paru-paru terutamanya kanser paru-paru sel bukan kecil (NSCLC) 
merupakan salah satu kanser yang merbahaya. Walaupun terdapat kaedah-kaedah 
rawatan yang pelbagai seperti pembedahan, kemoterapi, terapi radiasi bersasar, namun 
kadar kemandirian keseluruhan dalam 5 tahun hanya mencecah sebanyak 18.2 %. 
Kadar kematian pesakit NSCLC yang tinggi sebahagiannya adalah disebabkan 
kekurangan cara yang effektif untuk mengenalpasti penyakit contohnya melalui 
penanda-penanda bio. Masa kini, bahan-bahan bioaktif bersumberkan tumbuh- 
tumbuhan berpotensi sebagai agen antikanser. Salah satu tumbuhan berpotensi 
tersebut ialah Annona muricata Linn ataupun juga dikenali sebagai durian belanda atau 
graviola. Tumbuhan ini telah dilaporkan dengan meluas mempunyai bahan fitokimia 
yang bernilai yang berkemungkinan dapat dibangunkan sebagai agen penghalang 
perkembangan kanser. Tumbuhan tropika ini telah menunjukkan aktiviti 
antiproliferatif dan antikanser melalui kajian kultur sel secara in vitro dan kajian 
terhadap binatang secara in vivo. Ekstrak A. muricata L. dilihat dapat memberi kesan 
perencatan terhadap pelbagai jenis sel kanser, yang meliputi pelbagai jenis mekanisma 
tindakbalas. Walaubagaimapun, cara tindakbalas dan interaksi molekul yang 
ditunjukkan oleh tumbuhan ini masih belum dapat dirungkai sepenuhnya. Dalam 
kajian ini, kaedah sambutan permukaan telah digunakan untuk mengoptimumkan 
proses pengekstrakan daun A. muricata L. menggunakan kaedah ultrasonik (UAE) dan 
kaedah penyusutan (ME). Rekabentuk komposit berpusat telah digunakan untuk 
mengoptimumkan aktiviti antioksida bagi kedua-dua ekstrak. ME telah menunjukkan 
aktiviti antioksida yang tinggi dengan berbanding UAE dengan masing-masing 
merekodkan bacaan 83.3 % dan 31.6 %. Namun begitu, melalui kajian tahap toksik 
terhadap sel yang telah dilakukan menggunakan teknik MTT, UAE menunjukkan 
kesan toksik yang lebih ketara terhadap sel NSCLC (HLFa) dengan IC50 139.6 p,g/mL 
berbanding dengan ekstrak ME dengan IC30 108.4 p,g/mL. Kesan kedua-dua ekstrak 
terhadap pengeluaran nitrik oksida (NO) dalam sel-sel HLFa juga telah dinilai 
menggunakan Griess reagent system. Ekstrak-ekstrak ini dilihat mengurangkan 
pelepasan nitrit di dalam media yang dapat disimpulkan sebagai pengurangan 
pengeluaran NO. Teknik apoptosis Caspase 3/7 telah digunakan untuk mengesan sel- 
sel HLFa yang mengalami apoptosis selepas inkubasi. Ekspresi gen mRNA seperti 
HMGB1, BCL2 dan BAX  telah dinilai. Penilaian keputusan ekspresi gen telah 
menunjukkan kemungkinan penglibatan gen-gen ini di dalam tindakbalas antikanser 
A. muricata L. Di akhir kajian ini, interaksi dok molekul in siliko antara beberapa 
komponen fitokimia dari A. muricata L. dengan protein-protein seperti Bcl-2, Bcl-w 
dan Mcl-1 telah dianalisa. Kompleks yang terhasil dari interaksi tersebut telah dinilai 
kestabilannya menggunakan proses pemilihan simulasi molekul dinamik. Kewujudan 
anonaine di dalam UAE dan ME telah disahkan melalui teknik HPLC masing-masing 
dengan kepekatan 10.6 ppm dan 10.7 ppm.
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CHAPTER 1
INTRODUCTION
1.1 Research Background
Lung cancer is a major healthcare problem in Malaysia and across the globe. 
This disease is one of the most prominent cause of cancer-related mortality; about 40% 
cases was reported in developing countries like Malaysia [1]. In 2012, approximately
1.8 million cases were recorded with more than 80% of the proportion succumb to this 
fatal disorder. In Malaysia, lung cancer is the leading cause of cancer-death among 
males population and the fifth cause among females with about 13.8% and 3.8% cases 
respectively [2,3]. Lung cancer is among the cancers that constitute more than 58% of 
the projected global cancer burden [4]. In 2030, the leading cancer locations include 
lung, prostate and melanoma for men, and breast, thyroid and uterine for women [5]. 
There are three major types of lung cancers: non-small cell lung cancer (NSCLC), 
small cell lung cancer (SCLC) and lung carcinoid tumor. Despite numerous efforts -  
ranging from cancer immunotherapy to natural-derived anticancer agents -  have been 
taken in the recent years in pursuit to puzzle out the way to combat this incurable 
malady, the ‘war’ against cancers is getting more perplexing and gripping. T he hard- 
truth reality is that some part of cancer mechanism -  up to the present time -  is obscure; 
no individual in scientific community could authoritatively explain the ‘actual’ causes 
of cancers and how to prevent it let alone to cure it. However, in the recent years, 
natural-derived products such as plant-based products have gained wide interest. 
Reflection o f this circumstances can be seen from the report of World Health 
Organization (WHO) which stated that more than 80% of the global population relies 
on plant-based traditional medicine for their primary healthcare; this has raised up the 
possibility o f plant-derived substances to be the potential remedy everyone is looking 
for [6,7]. For the record, there are more than 3000 plant species being applied in the 
treatments of cancer-like diseases including swelling, abscesses, calluses, warts and 
polyps prompting the birth of about 60% of the currently available anticancer drugs
[8,9]. The application o f plant-derived substances as anticancer drugs such Taxol is 
beneficial to consumers as these substances exert fewer adverse effects, and they are 
cost-effective alternative [10,11].
As one of the most arguably potential source of anticancer agent, Annona 
muricata Linn, has been the subject of extensive researches for a number of years. 
Groups of phytochemical compounds including flavonoids, alkaloids and annonaceous 
acetogenins (ACGs) and several types o f extracts from A. muricata L. have been the 
candidates for anticancer drugs -  widely manipulated to determine their characteristics 
and mode of actions. They have been reported to eliminate cancer cells and disrupt 
cancer cells development through numerous numbers o f mechanisms in cell culture 
studies as well as in animal studies. For instance, A. muricata L. leaves ethyl acetate 
extract inhibited proliferation of lung cancer A549 cells via mitochondrial-mediated 
pathway with the involvement of NF-kB, a cell signaling regulator [12]. Likewise, 
commercialized leaves water extract of A. muricata L. minimized pancreatic 
metastasis and tumorigenicity o f implanted pancreatic tumors [13]. A synergistic study 
of major bioactive phytochemicals (flavonoids and ACGs) from A. muricata L. leaves 
showed that these substances inhibited proliferation activity of prostate cancer cells 
and the cells’ clonogenic capacity [14]. On the other hand, (-)-anonaine, an alkaloid, 
demonstrated dose-dependent antiproliferation, DNA damage and antimigration in 
human lung carcinoma (H1299) cells [15]. Furthermore, it also stimulated cell cycle 
arrest in the similar cell line [15]. These indicate that more studies involving lung 
cancer such as NSCLC are welcomed, as there are room for manipulation and 
improvement.
NSCLC is the most common type of lung cancers accounting for about 80­
85%, including adenocarcinoma (ADC) and squamous cell carcinoma (SCC) [16]. 
NSCLC is a type of aggressive cancer in which cancer cells form in the lung tissues. 
Risk factors for NSCLC include smoking, secondary smoking, radiation, 
environmental factors, genetic (family history) and HIV. Despite diverse treatment 
methods such as surgery, chemotherapy, radiation and targeted therapies, the overall 
5-year survival rate for NSCLC is accounted for only 18.2% [17]. The high mortality 
rates for NSCLC are partially due to the lack of effective prognostic factors such as
biomarkers. NSCLC is associated with several symptoms including shortness of 
breath, chest pain, lost of appetite and tiredness. To date, there is no cure or preventive 
treatment for NSCLC; however, several factors -  including the stage of cancer, type 
of mutations in cancer and patients’ health -  may affect the chance of recovery and 
treatment. A meta-analysis study involving 2651 NSCLC patients has detected the 
higher High Mobility Group Box 1 (HMGB1) expression in NSCLC cells than that in 
the healthy cells [16]. Thus, identifying the expression and behavior of novel 
prognostic factors like HMGB1, as biomarkers, may be a clinically useful tool for early 
detection of NSCLC and for potential cancer therapeutic target.
HMGB1, an extracellular damage-associated molecular pattern (DAMP), is a 
vital regulator of cell death and cell survival. It possesses several important functions 
in many diseases especially inflammatory diseases and cancers [18-20]. Its 
overexpression is linked to the hallmarks of cancer including angiogenesis capacity, 
apoptosis evasion, insensitivity to growth inhibitors, tissue invasion and metastasis, 
inflammation, self-sufficiency in growth signals and unlimited replicative potential 
[21]. The expression of vascular endothelial growth factor (VEGF), one of the main 
angiogenic factors, in ovarian carcinoma (SKOV3) cells was reduced with the 
interference of HMGB1 [22]. During cell death mechanisms, including apoptosis and 
necrosis, HMGB1 release was observed in pancreatic cancer (Panc-1) and cervical 
cancer (HeLa) cell lines [23]. Overexpression of HMGB1 in colorectal cancers had 
contributed significantly in tumor progression and tumors’ ability to metastasize [24]. 
While in NSCLC, HMGB1 enhanced the increase in cancer cells migration ability 
through the activation of TLR4/NF-kB signaling -  inducing metastasis [25]. It was 
revealed that the protein level o f HMGB1 in patients with NSCLC of TNM Stages III- 
IV was significantly higher as compared to TNM Stages I-II, indicating that HMGB1 
plays a crucial role in the progression of NSCLC [26]. These also demonstrated that 
HMGB1 expression could be regarded as important prognostic biomarker in cancers 
development specifically for NSCLC diagnosis, thus making it particularly interesting 
as potential therapeutic targets for cancer drug discovery.
Many studies have examined the relationship HMGB1 expression and NSCLC. 
Even though most of the results remain unsettled, some study has shown significance
correlation [26]. Hence, the present study focuses to investigate the mechanism 
involved in the effect of A. muricata L. leaves extract on the expression level of 
HMGB1 and several other biomarkers involved in regulating apoptosis in NSCLC. 
This study would provide additional information to the present anticancer knowledge 
and future research.
1.2 Problem Statement
A. muricata L. has long been postulated to possess anticancer properties against 
various types of cancer. The plant bioactive constituents such as ACGs have been 
identified to be vital contributors to anticancer effects, leading to its characterization 
and isolation. Even though the researches involving ACGs have been carried out for 
few decades, these compounds have never been commercialized or developed as 
anticancer drug for clinical test. These circumstances prompt a wave of questions 
debating the idea with hope that the premise relating to the anticancer effect of A. 
muricata L. is not just another scientific blunder.
From a local perspective, there have been a growing number of products based 
on A. muricata L . such as health supplement capsule, pill, juice and ice cream. The 
common conception among the public in Malaysia is that by consuming these 
products, their detrimental health could be ameliorated thus preventing them from 
succumbing to cancer. Therefore, there is huge responsibility lies within scientific 
community to clear the air to avoid any further misunderstanding that is not beneficial 
for the society in large.
In hope that A. muricata L. might display significant effect against lung cancer 
cells at the end of this study, the current research adds fresh and deepening information 
to the current anticancer knowledge. Even though NSCLC is the leading contributor 
of cancer mortality, there is lack o f A. muricata L. anticancer study on this type of lung 
cancer cell. It was reported that the high 5-year survival rate for NSCLC (18.2%) are 
due to the inadequacy of functional prognostic biomarkers and proper treatment [27]. 
This shortfall is due to difficulties in diagnosing NSCLC; patients are diagnosed at
advanced stages with distant and local metastases. The discovery of HMGB1 as 
potential effective markers for early diagnosis of NSCLC has allowed this biomarker 
to be the subject of thorough experimentations. In silico molecular docking and 
molecular dynamic (MD) simulation were also applied to investigate the intriguing 
possibility of A. muricata Linn’s bioactive compounds namely annonaceous 
acetogenins (ACGs) to possess Bcl-2 antiapoptotic inhibitory properties. Through 
molecular docking approach, the affinity o f the compounds of interest towards Bcl-2 
antiapoptotic proteins would be determined and possible interaction between amino 
acids and compounds would be crucial information for development o f anticancer drug 
using ACGs.
Thus, the understanding upon the underlying mechanism triggered by 
potential anticancer agent such as A. muricata L. extract in NSCLC would certainly 
ignite a slight hope in this long-running battle. This study is the first to evaluate the 
correlation between A. muricata L. effect and release of HMGB1 during cell death 
mechanism in NSCLC.
1.3 Research Objectives
The main objective of this study was to investigate the mechanistic effect 
induced by A. muricata L. optimized leaves extracts in NSCLC. The objective is 
further separated into several other objectives as listed below:
(a) To optimize the extraction parameters for high yield of A. muricata L. extracts
(b) To determine the antioxidant activity of the optimized extracts
(c) To investigate the effect of the optimized extracts on HMGB1 gene expression 
in NSCLC cells
(d) To characterize the in silico molecular interactions of the plant’s bioactive 
compounds
1.4 Scope of the Study
The scope of this research are as listed below:
1. Antioxidant-response optimization of ultrasonic-assisted extraction 
parameters (time, amplitude, ratio) and maceration extraction 
parameters (time, ratio, speed) of A. muricata L. leaves by using 
response surface methodology.
2. Determination of the antioxidant activity of the extracts by using 2, 2, 
diphenyl-2-picryl-hydrazyl (DPPH) free radical scavenging assay.
3. Cytotoxicity and anti-proliferation activities determination of the 
extracts by using 3-(4,5-dimethlthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) against human lung epidermoid carcinoma (HLFa) 
cells and human fibroblast cells (HSF1184).
4. Nitric oxide (NO) determination by using nitrite concentration assay.
5. Determination of apoptotic activity by using apoptosis detection 
assay.
6. Quantification of gene expression of BCL2, BAX  and HMGB1 by 
using real-time polymerase chain reaction (RT-PCR).
7. Characterization of binding interactions involving acetogenins of A. 
muricata L. and Bcl-2 antiapoptotic proteins, by using in silico 
molecular docking software, AutoDock 4.2 and molecular dynamics 
(MD) simulation.
8. Screening of bioactive compounds (ACGs) in the extracts by using 
High Performance Liquid Chromatography (HPLC).
1.5 Significances of the Study
The current study presents several novel contributions as well as additional 
knowledge in the field of A. muricata L anticancer research. The present study 
emphasizes the effect of extraction method on antioxidant effect response of A. 
muricata L and their correlation to antioxidant activities. This study is among a few
studies, which have been done to optimize the ultrasonic-assisted and maceration 
extractions, and comparison of anticancer effects between both optimized extracts 
provide new information to this particular field of research. This study also highlights 
the potential o f A. muricata L. extracts to be further developed as anticancer agent 
against lung cancer especially NSCLC. Furthermore, as the effect of plant extracts on 
HMGB1 has never been explored before, this study would be the first to offer novel 
report upon A. muricata L. mechanistic activity against HMGB1 in NSCLC, in 
addition to other regulators such as Bcl-2 and Bax that could be a steppingstone to 
future anticancer studies as well as provides insight on the novel understanding of 
therapeutic potential o f HMGB1 as prognostic biomarker.
1.6 Thesis Structure and Organization
This thesis comprises five chapters. The first chapter serves as a backbone of 
the whole thesis. It covers the underlying premise that led to the initiation of this study. 
The idea was presented in summarized language, of which consists of research 
background, problem statement, objective, scope and significances o f the study.
Chapter 2 gives thorough reviews and discussions on newest literatures 
available. In addition, it discusses the arguable potential o f A. muricata L. as candidate 
for anticancer agent. It also reviews the prevalence of lung cancer.
Chapter 3 elucidates the selected experimental-methodologies, of which were 
conducted to present the evidences for the hypothesis of the present study.
Chapter 4 puts forward the observed results together with the discussion of the 
findings that covers the anti-oxidative characteristics of A. muricata L. extract, the 
gene expression analysis of BCL2, BAX  and HMGB1 in lung cancer cells and the in 
silico virtual screening analysis.
Chapter 5 concludes the current study and summarizes the outcome. It also 
recommends suggestions for future researches.
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